ANNUAL GENERAL MEETING OF MEDIRÄTT AB

The shareholders of MediRätt AB, 556762-3391 (the "Company") are hereby invited to the Annual General Meeting on Wednesday, 10 April 2019 at 2:00 p.m. at Priority, Skeppsbron 24, Stockholm, Sweden

Right to participate and notification of attendance

Shareholders who wish to participate in the Annual General Meeting must firstly be included in the shareholders' register maintained by Euroclear Sweden AB as of Thursday, 4 April 2019, and secondly notify MediRätt AB in writing by post, c/o iZafe AB, Grev Turegatan 11 A, SE-114 46 Stockholm, Sweden, by e-mail, info@mediratt.com, or by telephone +46 8 765 66 33, no later than 12:00 Thursday, 4 April 2019. The notification shall state the shareholder's full name, personal identity or corporate registration number, shareholding of A shares and B shares respectively, address and daytime telephone number, as well as, where applicable, information about any proxies, or assistants (not more than 2). When applicable, complete authorisation documents, such as certificates of registration or the equivalent, shall be appended to the notification.

Nominee shares

Shareholders whose shares have been registered with a nominee must, through the bank or securities broker administering the shares, temporarily re-register their shares in their own names in order to be entitled to participate in the Annual General Meeting. Such re-registration, which usually will take a couple of days, must be completed with Euroclear Sweden AB not later than Thursday, 4 April 2019, entailing that the request for re-registration must be made to the nominee well in advance of this date.

Proxy etc

Shareholders represented by proxy shall issue a written and dated power of attorney for the proxy. If the power of attorney is issued on behalf of a legal entity, a certified copy of a certificate of registration or corresponding document stating the right to sign for the legal entity shall be appended to the power of attorney. The period of validity of the power of attorney and certificate may be a maximum of five years from the date of issuance. A copy of the power of attorney and, where applicable, the relevant certificate, should be sent by post to the Company at the address stated above well in advance of the Annual General Meeting, to facilitate the entry to the Annual General Meeting. The power of attorney in original, as well as the relevant certificate of registration, shall be presented at the Annual General Meeting. Proxy forms are available at www.mediratt.com, and will also be sent to shareholders who so request and inform the Company of their postal address.

Proposed agenda:

  1. Election of Chairman of the Meeting.
  2. Preparation and approval of the voting list.
  3. Approval of the agenda.
  4. Election of one or two persons to verify the minutes.
  5. Determination as to whether the Meeting has been duly convened.
  6. Presentation of the annual accounts and the audit report, as well as, where applicable, the consolidated accounts and the audit report on the consolidated accounts.
  7. Resolution regarding
    a. the adoption of the income statement and the balance sheet, as well as, where applicable, the consolidated income statement and the consolidated balance sheet
    b. disposition of the Company's profit or loss according to the adopted balance sheet,
    c. the discharge from liability for the members of the Board of Directors and the Chief Executive Officer.
  8. Determination of the number of members of the Board of Directors and auditors, as well as, where applicable, deputies.
  9. Determination of remuneration to the Board of Directors and the auditors.
  10. Election of the members of the Board of Directors and, where applicable, auditors and the deputy auditor, if any.
  11. Proposal for resolution on authorisation for the Board of Directors to resolve on issues of shares, warrants and convertibles.
  12. Proposal for resolution on amendments to the Articles of Association with regards to the Company name, the limits to share capital and the number of shares and the convening of General Meetings.
  13. Proposal for resolution on set-off issue.
  14. Proposal for resolution on issue of warrants with deviation from the shareholders' preferential rights.
  15. Proposal for resolution on issue of warrants with deviation from the shareholders' preferential rights, as well as approval of transfer of warrants to certain employees.
  16. Closing of the Meeting.

Proposed resolutions

Item 1: Election of Chairman of the Meeting

Shareholders representing 49.43 % of the votes in the Company propose that Carl-Johan Merner is elected Chairman of the Meeting.

Item 7.b): Resolution regarding disposition of the Company's profit or loss according to the adopted balance sheet

The Board of Directors proposes that all funds available for the Annual General Meeting are carried forward.

Item 8-10: Determination of the number of members and deputy members of the Board of Directors and auditors, remuneration to the Board of Directors and the auditors, and election of the members and deputy members of the Board of Directors and auditors

Shareholders representing 49.43 % of the votes of the Company propose the following:

- the number of members of the Board of Directors shall be four ordinary members and one deputy. The number of auditors shall be one.
- no remuneration shall be paid to the Board of Directors and that remuneration to auditors be paid in accordance with approved invoices.
- re-election of Viveca Gyberg, election of Carl-Johan Merner, Carl Sjönell, and an additional member of the Board of Directors to be named later as members of the Board of Directors and Göran Sjönell as deputy, as well as that Carl-Johan Merner is elected as new Chairman of the Board of Directors. It was noted that the Honorary Chairman Anders Säfwenberg has declined to be re-elected as member of the Board of Directors.
- election of KPMG AB, with Authorised Public Accountant Mattias Johansson as auditor in charge, until the closing of the 2020 Annual General Meeting.

Item 11: Resolution on authorisation for the Board of Directors to resolve on issues of shares, warrants and convertibles

The general meeting resolves to authorise the Board of Directors, for the period up to the next Annual General Meeting, whether on one or several occasions and whether with or without pre-emption rights for the shareholders, to adopt resolutions to issue new shares, convertible debentures and warrants. Such new issue resolutions may include provisions of payment in cash and/or payment by way of contribution of non-cash consideration or by set-off of a claim or that subscription shall be subject to other conditions.

Majority

A resolution under item 11 is valid only if it has been approved by shareholders representing at least two thirds of the votes cast as well as the shares represented at the Meeting.

Item: 12 Resolution on amendments to the Articles of Association with regards to the Company name, the limits to share capital and the number of shares and the convening of a General Meeting

The Board of Directors proposes that the General Meeting resolves to amend the Articles of Association as follows.

Current wording:

§1 Company name

The company's name is MediRätt AB. The company is a public company (publ).

Proposed wording:

§1 Company name

The company's name is iZafe Group AB. The company is a public company (publ).

Current wording:

§4 Share capital

The share capital shall amount to not less than SEK 10,700,000 and not more than SEK 42,800,000.

Proposed wording:

§4 Share capital

The share capital shall amount to not less than SEK 15,610,821 and not more than SEK 62,443,284.

Current wording:

§5 Number of shares

The number of shares shall amount to not less than 10,700,000 and not more than 42,800,000.

Proposed wording:

§5 Number of shares

The number of shares shall amount to not less than 15,610,821 and not more than 62,443,284.

Current wording:

§9 Notice convening a general meeting

Notice convening a general meeting shall be published in the Swedish Official Gazette, on the company's website www.mediratt.com as well as through a notice in SvD that a notice convening a general meeting has been published.

Notice convening the Annual General Meeting and notice convening an Extraordinary General Meeting where an amendment to the articles of association will be resolved on shall be published six weeks, at the earliest, and four weeks, at the latest, prior to the general meeting. Notice convening any other Extraordinary General Meeting shall be published six weeks, at the earliest, and two weeks, at the latest, prior to the general meeting.

Proposed wording:

§9 Notice convening a general meeting

Notice convening a general meeting shall be published in the Swedish Official Gazette, on the company's website and through a notice in SvD that a notice convening a general meeting has been published.

Notice convening the Annual General Meeting and notice convening an Extraordinary General Meeting where an amendment to the articles of association will be resolved on shall be published six weeks, at the earliest, and four weeks, at the latest, prior to the general meeting. Notice convening any other Extraordinary General Meeting shall be published six weeks, at the earliest, and two weeks, at the latest, prior to the general meeting.

Majority

The Board of Directors' proposal for amendments to the Articles of Association with regards to the Company name, the limits to the share capital and the number of shares and the convening of a general meeting under item 12 requires that the resolution is supported by shareholders holding at least two thirds of both the votes cast and the shares represented at the general meeting

Item 13: Resolution on set-off issue

The Board of Directors proposes that the Meeting resolves to carry out a private placement in respect of 825,240 series B shares, entailing an increase in the share capital of SEK 825,240. The resolution shall otherwise be governed by the following terms and conditions.

  1. The right to subscribe for the new shares shall vest in the creditors listed in the Board of Directors' report referred to in Chapter 13, section 7 of the Companies Act on set-off rights, dated 7 March 2019, published on the Company's website www.mediratt.com. The reason for not applying the shareholders' pre-emption rights is to settle existing debts in a time and cost efficient manner, while at the same time promoting a long term alignment of interests and loyalty among the Board of Directors and management without straining the Company's liquidity.
  2. For each share of series B subscribed for, SEK 18 shall be paid. The basis for the subscription price is the market value of the share. Payment shall be made by set-off of a claim in accordance with the Board of Directors' report.
  3. Subscription through payment for the newly-issued shares shall take place within three weeks of the date of the resolution to issue new shares.
  4. The board of directors shall be entitled to extend the subscription period.
  5. The new shares entitle the holder to a dividend as from the date on which the shares are entered in the share register.
  6. The Board of Directors or a person appointed by the Board of Directors is authorised to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office.

Majority

The proposal for resolution on set-off issue of shares to members of the Board of Directors and the Chief Executive Officer of the Company under item 13 requires that the resolution is supported by shareholders holding at least nine tenths of both the votes cast and the shares represented at the Meeting.

Item 14: Resolution on issue of warrants with deviation from the shareholders' preferential rights

The shareholder Sten Röing propose that the annual general meeting of shareholders shall resolve to issue a maximum of 2,200,000 warrants, which may result in a maximum total increase in the company's share capital of SEK 2,200,000. The warrants shall entitle to subscription of new shares of series B in the company.

The following terms shall apply to the issuance:

  1. The warrants may, with deviation from the shareholders' preferential rights, be subscribed for by members of the board of directors and the secretary of the board of directors. The persons entitled to subscribe for warrants shall be entitled to subscribe for at most 100,000 - 500,000 warrants each. The proposed allocation to each subscriber will be set forth in the shareholder's complete proposal.
  2. The purpose of the issuance and the deviation from the shareholders priority right is, to offer members of the board of directors and the secretary of the board of directors increased ownership in the company. The purpose is to create a common interest for the company's shareholders and its board of directors to work for and aim at the company achieving the best development possible with respect to its business and value.
  3. The warrants shall be subscribed for no later than three weeks from the date of the resolution to issue the warrants on a separate subscription list.
  4. A subscription price of SEK 0.06 shall be paid for each warrant. The basis for the subscription price is the market value of the warrants according to the Black & Scholes valuation model.
  5. Payment for the warrants subscribed for shall be made in cash within four weeks of the time of subscription.
  6. Each warrant entitles to subscription of one new share of series B in the company at a price of SEK 11. Subscription for new share by exercise of warrant shall be made during the period from when the warrants are registered by the Swedish Companies Registration Office up to and including 10 April 2021 or the earlier date set forth in the terms for the warrants.
  7. A new share of series B subscribed for by exercise of a warrant has a right to dividends as of the first record day for dividends following registration of the new share issue with the Companies Registration Office.
  8. The other terms for the warrants are contained in the shareholder's complete proposal.
  9. It is proposed that the board of directors or a person appointed by the board of directors be authorised to make such minor adjustments in the above resolution that may be required in connection with the registration with the Swedish Companies Registration Office.

Supplementary information

  1. Dilution and effects on key performance metrics
    1.1 As of the date of the proposal, the company has issued 15,610,821 shares. At the annual general meeting held on 10 April 2019, it is proposed that the company shall resolve on a set-off issue. Provided that the resolution on the set-off issue is adopted, the company will, thereafter, have issued 16,436,061 shares.
    1.2 Provided that all warrants of series TO7 are exercised to subscribe for shares, the number of shares and votes in the company will increase by 3,200,000 (with reservation for any recalculation under the terms for the warrants), which corresponds to a dilution of approximately 20.5 percent of the number of shares and 15.2 percent of the number of votes in the company prior to the abovementioned set-off issue, and approximately 19.5 percent of the number of shares and 14.7 percent of the number of votes in the company after the abovementioned set-off issue, respectively[1].
    1.3 The warrants are expected to have only a marginal effect on the company's key performance indicators, apart from dilution as set forth in item 1.2 above.
  2. Costs
    2.1 As the warrants of series TO7 shall be issued and transferred at market value at the time of issuance or transfer, respectively, the issue and transfers are not estimated to cause any costs for the company in the form of social security contributions.
    2.2 The costs for warrants of series TO7 are only estimated to consist of immaterial fees to external advisors and costs for implementation and administration of the warrants.

Majority

The proposal for resolution on issue of warrants with deviation from the shareholders' preferential rights under item 14 requires that the resolution is supported by shareholders holding at least nine tenths of both the votes cast and the shares represented at the Meeting.

Item 15: Resolution on issue of warrants with deviation from the shareholders' preferential rights, as well as approval of transfer of warrants to certain employees

The Board of Directors of MediRätt AB (publ), reg. no., 556762-3391, (the "company"), propose that the Annual General Meeting on 10 April 2019 resolves to carry out an issue of warrants of series TO7 to the company's wholly owned  subsidiary iZafe AB, reg. no. 556598-8812, ("iZafe"), pursuant to item A below, and on approval of transfer of warrants of series TO7 from iZafe to certain employees in the group of companies where MediRätt AB (publ) is the parent company (the "Group"), pursuant to item B below.

  1. Proposal for resolution regarding issuance of a maximum of 1,000,000 warrants with deviation from the shareholders' preferential rights

The board of directors propose that the annual general meeting of shareholders shall resolve to issue a maximum of 1,000,000 warrants, which may result in a maximum total increase in the company's share capital of SEK 1,000,000. The warrants shall entitle to subscription of new shares of series B in the company.

The following terms shall apply to the issuance:

  1. Right to subscribe for 1,000,000 warrants shall, with deviation from the shareholders' preferential rights, vest in iZafe. iZafe shall have the right and obligation to transfer the warrants to employees in the Group pursuant to the proposal in item B below. iZafe shall not have the right to dispose of the warrants in any other way than what is proposed under item B below.
  2. The purpose of the issuance and the deviation from the shareholders priority right is, to offer employees increased ownership in the company. The purpose is to create a common interest for the company's shareholders and employees of the Group to work for and aim at the company achieving the best development possible with respect to its business and value.
  3. The warrants shall be subscribed for no later than three weeks from the date of the resolution to issue the warrants on a separate subscription list, Exhibit 1A to the Board of Directors' complete proposal.
  4. The warrants shall be issued at no consideration.
  5. Each warrant entitles to subscription of one new share of series B in the company at a price of SEK 11. Subscription for new share by exercise of warrant shall be made during the period from when the warrants are registered by the Swedish Companies Registration Office up to and including 10 April 2021 or the earlier date set forth in the terms for the warrants.
  6. A new share of series B subscribed for by exercise of a warrant has a right to dividends as of the first record day for dividends following registration of the new share issue with the Companies Registration Office.
  7. The other terms for the warrants are contained in Exhibit 1B to the Board of Directors' complete proposal.
  8. It is proposed that the board of directors or a person appointed by the board of directors be authorised to make such minor adjustments in the above resolution that may be required in connection with the registration with the Swedish Companies Registration Office.
  9. Proposal for resolution on approval of transfer of warrants series TO7 to employees

The Board of Directors proposes that the Meeting resolves to approve that iZafe transfers at most 1,000,000 warrants of series TO7 to employees in the Group on the following terms:

  1. The right to acquire warrants from iZafe shall vest in the following categories of employees in the Group in the amounts indicated as determined by the Board of Directors:
    A. The Chief Executive Officer of the Company ("Category 1") shall have the right to acquire 500,000 warrants.
    B. Certain other senior executives ("Category 2") shall be entitled to acquire at most 290,000 warrants in aggregate.
    C. Other employees ("Category 3") shall be entitled to acquire at most 210,000 warrants in aggregate.

The Board of Directors shall determine which employees in each category shall have the right to acquire warrants and how many warrants that each such employee shall have the right to acquire

An employee can apply for acquisition of a lower, but not higher, number of warrants than the person has the right to acquire.

  1. The warrants shall be transferred on market terms at a price established based on a calculated market value of the warrants at the time of the transfer.
  2. Application for acquisition of warrants pursuant to item 1 above shall take place at the time set by the Board of Directors. The Board of Directors has the right to extend the application period.
  3. Payment for warrants shall be made at the time determined by the Board of Directors. The Board of Directors has the right to extend the time for payment.
  4. To be entitled to acquire warrants from iZafe, the person determined by the Board of Directors shall, at the time of the acquisition, be employed in the Group and neither have terminated its employment or have been terminated. Furthermore, it is required that the acquisition of warrants is legally possible. A person who has signed a contract of employment with a company that is part of the Group but not yet commenced service shall be considered as employed in this context.
  5. Any warrants that are not transferred to employees as set forth above may be reserved for future recruitments and may, pursuant to instructions from the Board of Directors, at one or several occasions, be transferred to new employees in the companies included in the Group, whereupon corresponding principles for allocation, conditions to be entitled to acquire warrants and other terms as those set forth above shall apply.

Supplementary information

  1. Dilution and effects on key performance metrics
    1.1 As of the date of the proposal, the company has issued 15,610,821 shares. At the annual general meeting held on 10 April 2019, it is proposed that the company shall resolve on a set-off issue. Provided that the resolution on the set-off issue is adopted, the company will, thereafter, have issued 16,436,061 shares.
    1.2 Provided that all warrants of series TO7 are exercised to subscribe for shares, the number of shares and votes in the company will increase by 3,200,000 (with reservation for any recalculation under the terms for the warrants), which corresponds to a dilution of approximately 20.5 percent of the number of shares and 15.2 percent of the number of votes in the company prior to the abovementioned set-off issue, and approximately 19.5 percent of the number of shares and 14.7 percent of the number of votes in the company after the abovementioned set-off issue, respectively[2].
    1.3 The warrants are expected to have only a marginal effect on the company's key performance indicators, apart from dilution as set forth in item 1.2 above.
  2. Costs
    2.1 As the warrants of series TO7 shall be issued and transferred at market value at the time of issuance or transfer, respectively, the issue and transfers are not estimated to cause any costs for the company in the form of social security contributions.
    2.2 The costs for warrants of series TO7 are only estimated to consist of immaterial fees to external advisors and costs for implementation and administration of the warrants.

Majority

The proposal for resolution on issue of warrants with deviation from the shareholders' preferential rights under item 15 requires that the resolution is supported by shareholders holding at least nine tenths of both the votes cast and the shares represented at the Meeting.

Number of shares and votes

As of the day of this notice the Company has a total of 600,000 A Shares, corresponding to 6,000,000 votes, and 15,010,821 B Shares, corresponding to 15,010,821 votes. The compiled number of votes in the Company corresponds to 21,010,821 votes. The Company holds no treasury shares.

Shareholders' right to request information

Shareholders are reminded of their right, at the Annual General Meeting, to request information from the Board of Directors and the Chief Executive Officer pursuant to Chapter 7, Section 32 of the Swedish Companies Act.

Proxy forms and complete proposals for resolutions

Proxy forms and copies of the annual accounts and the audit report will be available at the Company's office at address stated above and at the Company's website, www.mediratt.com, and will be sent to shareholders whom so require. The Board of Directors' and the relevant shareholders' complete proposals for resolutions as well as other required documents will be available at the Company and will be sent to shareholders who so request and inform the Company of their postal address. Further information regarding all of the members proposed to comprise the Company's Board of Directors will be available at the Company's website, www.mediratt.com.

For information about the processing of personal data, please refer to the integrity policy on the Euroclear Sweden AB website, https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

[1] Calculations based on the assumption that the Annual General Meeting on 10 April 2019 resolves on an issue of 2,200,000 warrants of series TO7 to certain board members, with deviation from the shareholders' preferential rights, and on issue of 1,000,000 warrants of series TO7 to iZafe, with deviation from the shareholders' preferential rights, as well as of approval of transfer of warrants from iZafe to certain employees.

[2] Calculations based on the assumption that the Annual General Meeting on 10 April 2019 resolves on an issue of 2,200,000 warrants of series TO7 to certain board members, with deviation from the shareholders' preferential rights, and on issue of 1,000,000 warrants of series TO7 to iZafe, with deviation from the shareholders' preferential rights, as well as of approval of transfer of warrants from iZafe to certain employees.

Lidingö in March 2019

MediRätt AB
The Board of Directors

For further information please contact:
Carl Johan Merner, CEO MediRätt AB
E-mail: carl.johan.merner@mediratt.com

Nerladdningsbara filer

Läkemedelsrobot uppmärksammas av Rapport

Med anledning av Rapports reportage torsdagens 19:30-sändning den 25 juli om läkemedelsrobot vill vi informera om att det finns ett svenskt system vid namn Dosell.


Dosell - stort intresse, säkrare täckning men senare leveranser

Efter finjusteringar av mobilapplikationen och mjukvaran är Dosellsystemet nu ytterligare anpassat för att fungera smidigare och enklare för slutanvändaren. Dosell har analyserats i praktiken gällande larmflöden och beroende på kundens behov har olika standardflöden kartlagts. iZafe arbetar nu med att ta Dosell till regionsnivå i Sverige och fortsätter sprida sitt budskap runt om i Europa.


iZafe skriver ramavtal med Team Olivia

iZafe är sedan tidigare leverantör av personlarm till ett av Team Olivias 43 dotterbolag. Nu väljer Team Olivia att utöka samarbetet med iZafe vilket innebär att samtliga dotterbolag kommer implementera iZafes säkerhetslösningar. Team Olivia är det tredje i raden av de stora vårdbolagen som väljer iZafes lösningar.


iZafe beslutar om riktad nyemission och genomför kvittning av fordran till ett värde av 4 MSEK

iZafe meddelar att Svensk Konstruktionstjänst AB (SveKon), utvecklare av Dosellsystemet, investerar 3,5 MSEK i iZafe i en riktad nyemission. Därutöver investerar även iZafes f.d. styrelseordförande 550 TKR i iZafe i en riktad nyemission. iZafe styrelse har, med stöd av bemyndigande från årsstämman den 10 april 2019, fattat beslut om en riktad nyemission av 882 874 aktier av serie B till SveKon, samt 137 500 aktier av serie B till f.d. styrelseordförande, mot betalning genom kvittning av fordran till ett värde av 4 MSEK. Denna överenskommelse gjordes den 28 juni 2019.



iZafe inleder ett exklusivt samarbete med Nokas, en av Norges ledande leverantörer av säkerhetslösningar

iZafe tar stora kliv framåt och offentliggör idag ett exklusivt samarbete med säkerhetsbolaget Nokas i Norge. Nokas är en ledande totalleverantör av säkerhetslösningar och kontanthantering till offentliga och privata verksamheter.


iZafe startar sin Europasatsning - tecknar avtal med partners i Italien

iZafe har denna vecka, onsdag 12 juni, tecknat avtal med en aktör i Italien för att ingå i vårdkonceptet Sempli Farma, vars syfte är att minska vårdkostnader och effektivisera det italienska sjukvårdssystemet. Övriga partners i projektet är Vanadoni Salus, Ladurner Hospitalia, CBA och Farmacia Vigilanti Cama. iZafes vårdlösning Dosell kommer in som sista pusselbit och sluter distributionskedjan.


iZafe beslutar om riktad nyemission av 1 323 191 aktier av serie B till Sten Röing mot betalning genom kvittning av fordran till ett värde av cirka 6,2 miljoner kronor

iZafes styrelse har idag, med stöd av bemyndigande från årsstämman den 10 april 2019, fattat beslut om en riktad nyemission av 1 323 191 aktier av serie B till bolagets grundare Sten Röing mot betalning genom kvittning av fordran till ett värde av 6 219 000 kronor.


Nyfikna blickar riktade mot Dosell på Vitalismässan som genererade över 90 leads för iZafe

Den 21-23 maj deltog iZafe på Vitalismässan i Göteborg, Nordens ledande mötesplats för eHälsa. Över 6 000 deltagare samlades för att kommunicera innovationer, utbyta kunskap och bygga relationer. Syftet för iZafe var att sprida budskapet kring digitalisering inom sjukvården och visa upp Dosells funktion. Med ett maxat tryck i montern och stort intresse från potentiella kunder, partners och återförsäljare, både svenska och utländska, fortsätter kännedomen om iZafe och vårdlösningen Dosell spridas världen över.


Status Dosell - nu ute hos vårdtagare

iZafe meddelar med stolthet att 20-25 Doseller i dagsläget levereras till kund varje vecka. Tillsammans med kunderna har noggranna genomgångar av systemet utförts och Doseller placerats ut permanent hos vårdtagare.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär